TY - JOUR
T1 - Epstein-barr virus and cytomegalovirus in relation to testicular-cancer risk
T2 - A nested case-control study
AU - Akre, Olof
AU - Lipworth, Loren
AU - Tretli, Steinar
AU - Linde, Annika
AU - Engstrand, Lars
AU - Adami, Hans Olov
AU - Melbye, Mads
AU - Andersen, Aage
AU - Ekbom, Anders
PY - 1999/7/2
Y1 - 1999/7/2
N2 - An infectious etiology of testicular cancer has been suggested. We have evaluated seroreactivity against cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in relation to testicular-cancer risk in a case-control study, nested within a cohort of prospectively collected serum specimens from 293,692 individuals. For each of 81 cases of testicular cancer identified, 3 controls were randomly selected from the cohort. Serum IgG antibody titers against CMV and EBV were determined using enzyme-linked immunosorbent assays (ELISAs) and immunofluorescence methods. Odds ratios (OR) were obtained from conditional logistic-regression models. No association was found between CMV positivity and testicular cancer overall (OR = 1.08; 95% confidence interval 0.601.94); risk for testicular seminoma was increased among CMV seropositive [OR = 1.70 (0.80-3.59)], whereas seropositivity was associated with decreased risk for testicular nonseminoma [OR = 0.54 (0.19-1.56)] (p for heterogeneity, 0.09). For EBV, the risk for testicular cancer was increased among individuals seropositive for viral capsid antigen (VCA) [OR = 2.74 (0.62-12.12)]. The results lend some support to the hypothesis of an infectious etiology, and we propose that future studies should take into account age at infection.
AB - An infectious etiology of testicular cancer has been suggested. We have evaluated seroreactivity against cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in relation to testicular-cancer risk in a case-control study, nested within a cohort of prospectively collected serum specimens from 293,692 individuals. For each of 81 cases of testicular cancer identified, 3 controls were randomly selected from the cohort. Serum IgG antibody titers against CMV and EBV were determined using enzyme-linked immunosorbent assays (ELISAs) and immunofluorescence methods. Odds ratios (OR) were obtained from conditional logistic-regression models. No association was found between CMV positivity and testicular cancer overall (OR = 1.08; 95% confidence interval 0.601.94); risk for testicular seminoma was increased among CMV seropositive [OR = 1.70 (0.80-3.59)], whereas seropositivity was associated with decreased risk for testicular nonseminoma [OR = 0.54 (0.19-1.56)] (p for heterogeneity, 0.09). For EBV, the risk for testicular cancer was increased among individuals seropositive for viral capsid antigen (VCA) [OR = 2.74 (0.62-12.12)]. The results lend some support to the hypothesis of an infectious etiology, and we propose that future studies should take into account age at infection.
UR - http://www.scopus.com/inward/record.url?scp=0033516612&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0215(19990702)82:1<1::AID-IJC1>3.0.CO;2-L
DO - 10.1002/(SICI)1097-0215(19990702)82:1<1::AID-IJC1>3.0.CO;2-L
M3 - Journal article
C2 - 10360811
AN - SCOPUS:0033516612
SN - 0020-7136
VL - 82
SP - 1
EP - 5
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 1
ER -